Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination** of phenazopyridine and hyoscyamine, typically used to relieve symptoms associated with irritation of the urinary tract, such as pain, burning, urgent or frequent urination, and bladder spasms. **Phenazopyridine** acts as a urinary tract analgesic, providing local pain relief to the lining of the urinary tract; it does not treat the underlying cause of infection but soothes discomfort[3][4][1]. **Hyoscyamine** is an anticholinergic/antispasmodic that inhibits muscarinic acetylcholine receptors, thereby reducing smooth muscle spasms in the bladder and urinary tract and decreasing symptoms like urgency and cramping[5][1]. This combination does not have unique branded formulations commonly in use, but related combinations with similar ingredients have existed (often also containing barbiturates).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenazopyridine + hyoscyamine.